Showing 1951-1960 of 4941 results for "".
- High Rates of Skin Conditions Seen Among Urban-living Indigenous Kids in High-Income Countrieshttps://practicaldermatology.com/news/high-rates-of-skin-conditions-seen-among-urban-living-indigenous-kids-in-high-income-countries/2461421/Many urban-living Indigenous children and young people in high-income countries are burdened with atopic dermatitis and bacterial skin infections, according to Aasystematic analysis in Pediatric Dermatology. Invest
- IFPA Launches All the Colors We Are to Call Attention to Diversity in Psoriatic Diseaseshttps://practicaldermatology.com/news/ifpa-launches-all-the-colors-we-are-to-call-attention-to-diversity-in-psoriatic-diseases/2461419/IFPA is launching a new image library that raises awareness of diversity in psoriatic disease. IFPA is the global organization representing all people with psoriatic disease,. Go to any image database, and type “psoriasis” in the search bar. The results? Invariably
- Hydrafacial and Glytone Team Up to Launch New Boosterhttps://practicaldermatology.com/news/hydrafacial-and-glytone-team-up-to-launch-new-booster/2461414/The Beauty Health Company’s Hydrafacial is rolling out a new exfoliating booster co-created with Glytone. The Glytone AHA Resurfacing Cellular Booster leverages a unique combination of three alpha hydroxy acids (AHAs) that may help improve the appearance of skin surface and textur
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod
- Almirall’s New Psoriasis Campaign Sheds Light on How the Disease Affects Mental Health and Wellbeinghttps://practicaldermatology.com/news/almiralls-new-psoriasis-campaign-sheds-light-on-how-the-disease-affects-mental-health-and-wellbeing/2461407/Almirall and the International Federation of Psoriasis Association are launching the second edition of the "Shedding Light on Psoriasis" campaign for World Psoriasis Day 2022. Shedding Light on Psoriasis 
- EltaMD Honored in Fast Company Magazine’s 2022 “Brands That Matter” Listhttps://practicaldermatology.com/news/eltamd-honored-in-fast-company-magazines-2022-brands-that-matter-list/2461402/EltaMD has been named to Fast Company’s “Brands that Matter” list for its memorable campaign to increase awareness of skin cancer and how to prevent it. The list honors companies and nonprofits that have had an undeniable impact on business and culture. Skin
- Potential Hair Growth Breakthrough: Researchers Grow Mature Hair Follicles in Labhttps://practicaldermatology.com/news/potential-hair-growth-breakthrough-researchers-grow-mature-hair-follicles-in-lab/2461398/Japanese researchers have successfully grown hair follicles in the lab. The team created a system that produces fully mature hair follicles as well as hair as long as 3 millimeters after a few weeks' growth. The in vitro hair follicle model adds to the understanding of ha
- Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosishttps://practicaldermatology.com/news/seborrheic-dermatitis-survey-shows-burdensome-and-lengthy-path-to-diagnosis/2461396/Arcutis Biotherapeutics, Inc., shared results of a nationwide survey of adults with seborrheic dermatitis and the health care providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease. The online survey was conducted by T
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- Thirdhand Smoke Linked to Contact Dermatitis, Psoriasishttps://practicaldermatology.com/news/thirdhand-linked-to-contact-dermatitis-psoriasis/2461389/Acute exposure to thirdhand smoke on the skin elevates biomarkers associated with the initiation of skin diseases, such as contact dermatitis and psoriasis. “We found exposure of human skin to THS initiates mechanisms of inflammatory skin disease, and elevate